Pfizer’s COVID-19 antiviral Paxlovid brought in $7.5 billion in sales in Q3

Pfizer Inc.’s PFE, +3.14% COVID-19 antiviral Paxlovid brought in $7.5 billion in sales in the third quarter of the year, against a FactSet consensus of $7.6 billion. The drug company also reiterated guidance for Paxlovid revenues in 2022, saying it still expects $22 billion in sales for the year. The FactSet consensus is $22.5 billion. Pfizer’s stock has declined 21.1% so far this year, while the S&P 500 SPX, -0.41% has declined 18.7%.